Eli Lilly weight-loss drug found more effective than Novo Nordisk's OzempicProactive Investors • 07/09/24
Novo Nordisk's stock slumps after study finds Wegovy lags Lilly's Mounjaro in speed and scale of weight lossMarket Watch • 07/09/24
Is Eli Lilly Stock a No-Brainer Buy After Its FDA Alzheimer's Disease Drug Win?The Motley Fool • 07/09/24
Novo Nordisk shares down after analysis finds Lilly drug leads to better weight lossReuters • 07/09/24
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?The Motley Fool • 07/09/24
Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's OzempicInvestors Business Daily • 07/08/24
Eli Lilly's First Biotech Deal Of 2024, Buys Chronic Disease Player Morphic For $3.2BBenzinga • 07/08/24
GordonMD® Global Investments Portfolio Company, Radionetics Oncology, Announced Strategic Agreement with LillyBusiness Wire • 07/08/24
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel DiseasePRNewsWire • 07/08/24